Literature DB >> 11730310

Preventive strategies in chronic liver disease: part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise.

T R Riley1, A M Bhatti.   

Abstract

Chronic liver disease is the 10th leading cause of death in the United States. Hepatitis C virus infection is the most frequent cause of chronic liver disease and the most common indication for liver transplantation. Preventive care can significantly reduce the progression of liver disease. Alcohol and hepatitis C virus are synergistic in hastening the development of cirrhosis; therefore, patients with hepatitis C infection should abstain from alcohol use. Because superinfection with hepatitis A or B virus can lead to liver failure, vaccination is recommended. Potentially hepatotoxic medications should be used with caution in patients with chronic liver disease. In general, nonsteroidal anti-inflammatory drugs should be avoided; acetaminophen in a dosage below 2 g per day is the safest choice. Many herbal remedies are potentially hepatotoxic, and only milk thistle can be used safely in patients who have chronic liver disease. Weight reduction and exercise can improve liver function in patients with fatty liver.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11730310

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  4 in total

1.  Complementary and alternative medicine use in chronic liver disease patients.

Authors:  Leah M Ferrucci; Beth P Bell; Kathy B Dhotre; M Michele Manos; Norah A Terrault; Atif Zaman; Rosemary C Murphy; Grace R Vanness; Ann R Thomas; Stephanie R Bialek; Mayur M Desai; Andre N Sofair
Journal:  J Clin Gastroenterol       Date:  2010-02       Impact factor: 3.062

2.  Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations.

Authors:  Simona Rossi; David N Assis; Monica Awsare; Mark Brunner; Kevin Skole; Jitha Rai; Jocelyn Andrel; Steven K Herrine; Rajender K Reddy; Victor J Navarro
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Serum Basal Paraoxonase 1 Activity as an Additional Liver Function Test for the Evaluation of Patients with Chronic Hepatitis.

Authors:  Anand K Pyati; Chandrakanth K Halappa; Sudharani A Pyati; Vinod Wali
Journal:  J Clin Diagn Res       Date:  2015-11-01

4.  Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy.

Authors:  Valerio Iebba; Francesca Guerrieri; Vincenza Di Gregorio; Massimo Levrero; Antonella Gagliardi; Floriana Santangelo; Anatoly P Sobolev; Simone Circi; Valerio Giannelli; Luisa Mannina; Serena Schippa; Manuela Merli
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.